Fig. 2

Volcano plot comparing glomerular protein abundance between patients with IgAN and controls (a). Volcano plot comparison of glomerular-protein abundance between the immunosuppression therapy and supportive therapy groups of patients with IgAN (b). A P value of less than 0.05 and an absolute value of Log₂ (fold change) of greater than 0.58 were considered significant. Molecules significantly upregulated are shown on the right side in red, while those downregulated are shown on the left side in blue. Molecules that were not significantly different between the two groups appear in gray. Gene symbols related to the complement cascade are annotated. The diagram of complement pathway (c). The proteins which were detected more abundantly in the glomeruli of patients with IgAN compared to controls were colored according to fold-change levels. IgAN, IgA nephropathy; FC, fold change; CFHR, Complement factor H-related protein; CFH, Complement factor H; C1QB, Complement C1q subcomponent subunit B; C1QC, Complement C1q subcomponent subunit C; C1R, Complement C1r subcomponent; C3, Complement C3; C4A, Complement C4-A; C4B, Complement C4-B; C4BPA, C4b-binding protein alpha chain; C5, Complement C5; C6, Complement component C6, C7, Complement component C7; C8A, Complement component C8 alpha chain; C8B, Complement component C8 beta chain; C8G, Complement component C8 gamma chain; C9, Complement component C9; F2, Prothrombin; SERPING1, Plasma protease C1 inhibitor; CFP, Properdin; CFB, Complement factor B; CFD, Complement factor D; DAF, decay-accelerating factor; CR1, Complement receptor type 1; CFI, Complement factor I; CLU, Clusterin; VTN, Vitronectin; MAC, Membrane attack complex; MBL, Mannan-binding lectin; MASP, Mannose-binding lectin-associated serine protease.